Rivastigmine Mini-Tablet for Alzheimer's Disease
NCT06828289 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000
Last updated 2025-02-20
Summary
The objective of this study is to evaluate the efficacy and safety of rivastigmine mini-tablets in individuals diagnosed with mild to moderate Alzheimer's disease (AD).
Conditions
- Alzheimer's Disease
Interventions
- DRUG
-
Rivastigmine Mini-Tablet
Treatment group: Rivastigmine Mini-Tablet
- DRUG
-
Donepezil Hydrochloride
Control group: Donepezil Hydrochloride
Sponsors & Collaborators
-
Peking University First Hospital
lead OTHER
Principal Investigators
-
Yongan Sun, Phd · Peking University First Hospital
Eligibility
- Min Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-02-28
- Primary Completion
- 2026-12-31
- Completion
- 2026-12-31
More Related Trials
-
A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease
NCT01399125 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors
NCT01529619 ·Status: COMPLETED ·Phase: PHASE4
-
Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment
NCT00234637 ·Status: COMPLETED ·Phase: PHASE4
-
A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)
NCT00622713 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease
NCT00423085 ·Status: COMPLETED ·Phase: PHASE3
-
Lecanemab for Early Onset Familial Alzheimer's Disease
NCT06883019 ·Status: RECRUITING
-
Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease
NCT00099242 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44
NCT00948766 ·Status: COMPLETED ·Phase: PHASE4
-
16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients
NCT01948791 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease
NCT00663936 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease
NCT06702124 ·Status: RECRUITING ·Phase: PHASE3
-
Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's Disease
NCT00305903 ·Status: COMPLETED ·Phase: PHASE4
-
Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease
NCT00428389 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease
NCT00561392 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease
NCT05104463 ·Status: COMPLETED ·Phase: PHASE2
-
NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.
NCT02703636 ·Status: COMPLETED ·Phase: PHASE4
-
Octohydroaminoacridine Succinate Tablet for Mild-to-Moderate Alzheimer's Disease
NCT03283059 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study of RO7105705 in Healthy Participants and Participants With Mild-to-Moderate Alzheimer's Disease
NCT02820896 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison of Once Daily and Twice Daily Dosing on Safety and Tolerability of Memantine in Patients With Alzheimer
NCT02553928 ·Status: COMPLETED ·Phase: PHASE4
-
Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline
NCT00506415 ·Status: COMPLETED ·Phase: PHASE3
-
Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease
NCT01626391 ·Status: TERMINATED ·Phase: PHASE2
-
Investigator Initiated Trial of Galcanezumab Treatment in Alzheimer's Disease
NCT07323927 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Rivastigmine in the Management of Delirium
NCT01487317 ·Status: COMPLETED ·Phase: PHASE3
-
Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease
NCT00104442 ·Status: COMPLETED ·Phase: PHASE4
-
Rivastigmine in the Treatment of Postoperative Delirium: a Pilot Clinical Trial
NCT00835159 ·Status: COMPLETED ·Phase: PHASE4